---
title: >-
  Routinely Available Noninvasive Tests Perform Well in Identifying Patients
  with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational
  Cohort.
description: >-
  Explore this publication on real-world evidence: Routinely Available
  Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis
  Due to…
date: '2019-01-01'
category: Publications
tags:
  - AASLD
  - Poster Presentation
  - R&D
  - Care
  - Hepatology
  - MASH/MASLD
  - Pharma Partner
  - Health System Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/aasld/routinely-available-noninvasive-tests-perform-well-in/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: routinely-available-noninvasive-tests-perform-well-in
id: 676nvhMlY6mRZ3ORFkRvNb
contentType: article
---

## Challenge

While NITs had shown promise in clinical trial populations for identifying advanced fibrosis in NASH, their performance in real-world clinical practice—where patients are more heterogeneous and data quality varies—had not been validated, limiting confidence in their use for trial enrichment.

## Solution

The TARGET-NASH cohort was used to evaluate FIB-4, NFS, and VCTE against locally interpreted liver biopsies, reporting AUROC, sensitivity, specificity, and PPV/NPV for advanced fibrosis across the real-world population, with subgroup analyses by demographics and clinical variables.

## Impact

Demonstrating that NITs perform comparably in real-world practice to their performance in clinical trial populations validates their use for NASH trial enrollment enrichment, supporting sponsors in designing biopsy-sparing enrichment strategies acceptable to regulators.